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Abstract
Background: Improvements in knee osteoarthritis (OA) symptoms with platelet-rich plasma (PRP) have been
attributed to its ability to modify intra-articular inflammatory processes. Photo-activation of peripheral blood also
improves inflammatory mediators associated with OA, however combined photo-activated PRP (PA-PRP) has not
been investigated. This pilot study assessed the feasibility, safety and symptomatic and functional change following
injections of PA-PRP compared to hyaluronic acid (HA) in people with knee osteoarthritis (OA).
Methods: Thirty seven people with knee OA were enrolled in this double-blind randomized controlled pilot study
set in a sports medicine clinic. Participants were randomly allocated to receive three injections of either PA-PRP or
HA. The patients and the administering doctor were blinded to group allocation. Outcomes included recruitment
and safety data, 100 mm visual analogue pain score (VAS), the Knee Osteoarthritis Outcome Score (KOOS), Knee
Quality of Life (KQoL) scale, maximum hopping distance and number of knee bends in 30 s at four and 12 weeks.
Results: Twenty three (62 %) participants met the inclusion criteria, of which 12 (32 %) were randomized to the
PA-PRP group and 11 (30 %) to the HA group. Two participants did not complete the intervention and two
withdrew following their first assessment. Minor pain and swelling during the injection period was reported by
two participants from the PA-PRP group. The PA-PRP group demonstrated significant improvements in the VAS
(p < 0.01, ETA = 0.686), KOOS Pain (p < 0.05, ETA = 0.624), KQoL Physical (p < 0.05, ETA = 0.706) and KQoL Emotional
subscales (p < 0.05, ETA = 0.715) at four and 12 weeks. The PA-PRP group also significantly improved hoping
(p < 0.05, ETA = 0.799) and knee bends (p < 0.01, ETA = 0.756) at four or 12 weeks. The HA group showed
improvements on only the KOOS Function subscale at 12 weeks (p < 0.01, ETA = 0.602). After controlling for baseline
values, there were no significant between-group differences at either time-point.
Conclusions: This study provides proof-of-concept evidence concerning the feasibility and safety of PA-PRP
injections necessary to inform a larger clinical trial in people with knee OA. Our preliminary results also suggest
PA-PRP improves self-reported pain, symptoms and lower extremity function, however no between-group
differences were found. Photo-activated PRP may provide a safe and effective novel treatment for knee OA.
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Background
Osteoarthritis is a leading cause of musculoskeletal pain
worldwide and the knee is one of the most commonly
affected joints. Prevalence of knee OA is expected to
increase with an aging population and growing rates of
obesity, and projections of total knee replacements are
predicted to increase by approximately 600 % over the
next 25 years [1]. As there is currently no cure for OA,
treatment has focused on symptomatic relief with the
aim of reducing pain and disability and maintaining or
improving joint mobility [2]. Non-surgical treatments
including exercise and weight loss are recommended
due to poor symptomatic and functional outcomes with
surgical management [3]. However compliance with
non-surgical treatments is poor [4], whilst drug treat-
ments such as simple analgesics and non-steroidal anti-
inflammatory drugs are associated with adverse events
[2, 5, 6]. The addition of intra-articular injections with
hyaluronic acid (HA) products (viscosupplementation) has
also been recommended in patients unresponsive to non-
pharmacological or analgesic regimes [6], although this
treatment is also uncertain as efficacy is variable and on-
going treatment is required [7–9]. Given the progressive
nature of knee OA, and the serious limitations associated
with existing therapies, studies in to effective treatments
with potential disease-modifying effects are needed.
Recent research suggests that growth factors and other
cytokines released by platelets in response to injury or
pathology may modulate inflammatory processes and
contribute to the maintenance or regeneration of tissue
structures [10, 11]. Consequently, platelet-rich plasma
(PRP) injections have become an emerging treatment for
soft tissue healing associated with tendon and ligament
injury, bone mineralisation and cartilage regeneration
[12–14]. Upon application to the affected site, activated
platelets release growth factors and other bioactive mol-
ecules, and coagulation occurs to form a matrix that
promotes migration of additional cells to the area. Com-
bined, these factors may promote tissue healing and
modulate the aberrant inflammatory processes implicated
in the pathophysiology of OA [10–12].
Recent unblinded and non-randomized pilot and
prospective studies investigating the clinical efficacy of
intra-articular injections of PRP in patients with knee
OA have demonstrated clinical improvement in self-
reported pain and symptoms with no major adverse
events [10, 15–17]. Furthermore, a recent systematic re-
view found six randomized controlled trials reporting
clinical benefits of PRP in patients with knee OA [18],
however, only two were double-blinded with a matched
control procedure [19, 20], and neither of these evalu-
ated the effects of PRP on objective measures of lower
extremity function. This limits the ability to determine
whether symptomatic benefits translate to improved
mobility, which is critical given 80 % of people with OA
have movement limitations and 25 % cannot perform
daily activities [21].
The use of low-level light irradiation to activate per-
ipheral blood (photo-activation) has also been shown to
improve biological factors associated with osteoarthritis
[22, 23]. Studies have reported that photo-activation
decreases proinflammatory cytokines (interleukin 2 and 6)
and increases the concentration of leucocyte-derived anti-
inflammatory factors (interleukin 1 receptor antagonist)
[22, 23]. As such, this activation technique could be bene-
ficial in PRP preparations higher in leukocyte concentra-
tion. To date, only two case studies have investigated
combined photo-activation and PRP (PA-PRP) in degen-
erative conditions, reporting symptomatic improvements
in one patient with a chondral defect [24] and another
with knee OA [25]. There are currently no clinical trials of
PA-PRP in knee osteoarthritis. Therefore, the aim of this
double-blinded, randomized, controlled pilot study was to
determine the feasibility, safety and changes in pain,
symptoms and lower limb functional ability following
intra-articular injections of PA-PRP compared to HA in
patients with mild to moderate knee OA.
Methods
Trial design
This was a single centre, double-blind, randomized con-
trolled pilot study comparing PA-PRP to HA. We chose
HA as the active comparator as it is one of the most
commonly used injective treatments for knee OA [26],
and recent network meta-analyses have demonstrated
clinical benefits above intra-articular placebo injections
[27, 28]. Participants were recruited from the commu-
nity using online advertising and through existing data-
bases between June and August, 2011. An information
letter outlining potential risks and benefits was provided,
and participants were fully informed about the testing
protocol and procedures. The study was approved by the
Australian Catholic University Human Research Ethics
Committee, and all participants gave written informed
consent prior to the commencement of testing.
Participants
Based on recommendations for determining sample sizes
for pilot studies [29, 30], we enrolled 37 people with
knee OA to participate in the study (Fig. 1). To be
eligible, participants were required to have a diagnosis of
knee OA based upon the American College of Rheu-
matology knee OA clinical classification criteria [31],
radiographic evidence of Kellgren-Lawrence grade 2 or 3
knee OA [32] and be willing to discontinue analgesics
and anti-inflammatory medications (except Paracetamol)
for at least two weeks prior to commencing the inter-
vention and for the duration of the study. Only people
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with mild to moderate radiographic OA disease were
chosen based on recommendations from a recent sys-
tematic review of PRP in people with degenerative knee
pathology [33]. Exclusion criteria were systemic or in-
flammatory joint disease, history of crystalline or neuro-
pathic arthropathy, cancer or other tumour-like lesions,
immunosuppression or acute infective processes, preg-
nancy or lactation, other intra-articular lesions or treat-
ments in the previous six months or allergy to any test
substance.
Procedures
Group allocation and concealment was performed by an
independent staff member not involved with the assess-
ment of participants. Participants were randomly allo-
cated following baseline data collection on a 1:1 basis
using a computer generated randomization list. Both
groups completed the PA-PRP collection and activation
phase of the intervention as explained below, and the
syringe was then provided to the independent staff
member. The staff member either retained or discarded
the syringe containing the PA-PRP depending on group
allocation. The syringe containing the PA-PRP, or an
identical looking syringe containing HA (Synvisc® Hylan
G-F 20, Genzyme Biosurgery, Ridgefield, NJ, USA), was
then occluded and returned to the treating doctor for
administration. This process ensured the blinding of
both the patient and treating doctor. All injections were
performed at weekly intervals.
To obtain the PRP, 48.5 ml of the patient’s blood was
collected using venipuncture, then centrifuged (Premiere
XC-2000) at 2,000 rpm for five minutes. The plasma and
buffy coat containing platelets was drawn from the top
of the sample and placed in a sterile tube and
Fig. 1 CONSORT diagram demonstrating flow of participants through the trial
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centrifuged again at 3,000 rpm for three minutes. This
double-spin approach has been shown to produce PRP
that is higher in leukocytes [34], which was preferred for
this study as photo-activation is thought to act at least
in part by influencing the pro- and anti-inflammatory
properties of leukocytes [22, 23]. Three quarters of the
plasma was removed, 0.2 ml of sodium bicarbonate 8.4 %
was added to the tube and the platelet pellet was
reconstituted using the remaining plasma in a 3 ml
syringe. To activate the PRP, the syringe containing
the PRP then underwent low-level ultraviolet light irradi-
ation (Adilight-1, Adistem Ltd.) for five minutes consistent
with published protocols [23].
Participants were placed in a supine position and ster-
ile drapes were placed around the surrounding area.
Next, the participant’s symptomatic knee was cleaned
with chlorhexadine and iodine solution and the knee
was anaesthetised using an intra-articular injection of 5
ml of 1 % Xylocaine. Following activation, 3 ml of PA-
PRP or HA was injected under ultrasound guidance
(Logic i, GE Healthcare) into the symptomatic region
using an anteromedial approach. Following the injection,
passive flexion and extension of the knee was performed
10 times, after which the participant remained resting in
the supine position for approximately 10 min. Participants
were advised to take paracetamol if they experienced
any pain, and to limit their weight bearing activities
for the subsequent 24 h, followed by gradual resumption
of normal activities.
Outcomes
Prior to treatment, baseline demographic data was col-
lected. Feasibility was recorded using recruitment and
retention rates, and safety was assessed by recording the
number and nature of adverse events. Adverse events
were recorded weekly for the first month using partici-
pant phone calls, and at one and three month during the
follow up assessment visits. To evaluate symptom severity,
participants first completed a 100 mm Visual Analogue
Scale (VAS) to rate their average knee pain over the previ-
ous week, with terminal descriptors of “no pain” and
“worst pain possible” [35]. To document self-reported
symptoms, participants also completed the Knee Injury
and Osteoarthritis Outcome Score (KOOS) and the Knee
Quality of Life 26-item questionnaire (KQoL-26). The
KOOS is an OA disease-specific instrument for the assess-
ment of patient-relevant treatment effects. The KOOS
uses a five point Likert scale for scoring the three
Western Ontario and McMaster Universities Osteo-
arthritis (WOMAC) sub-scales of Pain, Stiffness and
Physical Function, with the additional inclusion of the
sub-scales Quality of Life and Sport and Recreation
[36]. The KQoL-26 is a self-reported quality of life instru-
ment developed to assess the severity of knee symptoms
and activity and work limitations in patients with knee
injuries. It is comprised of three sub-scales, including
Physical Functioning, Activity Limitations and Emo-
tional Functioning, and uses a five point Likert scale
for scoring [37].
Finally, recent research suggests that validated self-
report questionnaires and objective functional tests
should be employed in combination to fully assess
mobility-related outcomes in people with knee OA [38].
Consequently, two objective measures of lower extremity
functional ability (maximum single leg hop and number
of knee bends in 30 s) were also completed by partici-
pants as described previously [38, 39]. The maximum
single leg hop for distance required a hop to be performed
from a starting position of balancing on one leg, and fin-
ishing position of landing and balancing on the same leg
to a stationary stance position. The maximum number of
knee bends performed in 30 s required the participant to
balance on one leg and perform as many shallow knee
bends (until they couldn’t see their toes past the bent
knee, or approximately 30 degrees) as they could in a 30 s
period without touching the elevated foot on the ground.
All surveys and functional tests were completed at
baseline, four weeks and at a final follow-up at 12 weeks
following the final treatment injection, as this timeframe
has been shown to demonstrate symptomatic improve-
ments in previous studies using other PRP preparation
methods [19, 20, 40].
Statistical analysis
The Statistical Package for Social Sciences (SPSS) software
(Version 17) was used to analyse the data. Normality was
assessed using skewness and kurtosis statistics and the
Shapiro-Wilk test. To determine whether PA-PRP and
HA had an effect on outcome variables, one way Repeated
Measures Analysis of Variance (RM ANOVA) were con-
ducted to compare baseline, four and 12 week follow-up
scores for the VAS, KOOS, KQoL-26 and functional tests
for each group. An analysis of covariance (ANCOVA) was
used to assess between-group changes in the primary and
secondary outcomes, with group allocation as the fixed
factor and corresponding baseline outcome values as
covariates. This technique has been reported to be the op-
timal method to analyse continuous data in clinical trials
[41]. An alpha level of p < 0.05 was used to determine stat-
istical significance.
Results
Twenty three (62 %) of the 37 enrolled people with knee
OA (males = 16, females = 7, age = 51.20 ± 12.00 years,
mass = 96.35 ± 18.14 kg, height = 178.00 ± 10.10 cm,
BMI = 29.24 ± 9.52) met the inclusion criteria. Two partic-
ipants did not complete the allocated intervention; one
from the PA-PRP group who withdrew due to minor
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injection-related pain and swelling which resolved without
further treatment, and one from the HA group who suf-
fered an acute meniscal tear unrelated to the treatment.
Two additional participants withdrew from the study due
to other unrelated injuries after the four week follow up
assessments. Consequently, data was available for 21 par-
ticipants (PRP = 11 participants, HA = 10 participants) for
the four week follow up and for 19 participants at 12
weeks (Fig. 1). Participant characteristics are displayed in
Table 1. No differences were found between the two
groups (p > 0.05).
No treatment-related major adverse events were expe-
rienced by participants. Two participants from the PA-
PRP group experienced minor pain and swelling during
the injection period believed to be related to the injection
technique. Both participants completed the injection
course, and had resolution of symptoms by the following
week. No further adverse events were experienced during
the intervention or follow-up period.
Average pain recorded using the 100 mm VAS reduced
from baseline at the four and 12 week follow up time
points for both the PA-PRP and HA groups (Table 2).
Although there was a slight increase in pain at the 12
weeks in the PA-PRP group, this still represented a 24 %
improvement above baseline pain. Repeated Measures
ANOVA revealed the reduction in pain was significant
for the PA-PRP group only (p = 0.017). Post hoc tests
showed that the reduction in pain at four weeks was sig-
nificantly less than baseline (27.67 mm, 95 % CI 12.39 to
42.95, p = 0.003, ETA = 0.686), however the 11.4 mm
reduction in VAS at 12 weeks was not statistically sig-
nificant. No significant reductions in pain were found
for the HA group.
For the PA-PRP group, significant improvements were
found at both follow up time points in the KOOS Pain
subscale (4 weeks: 13.33, 95 % CI 4.66 to 22.01, p = 0.007;
12 weeks: 11.67, 95 % CI 2.99 to 20.34, p = 0.014, ETA =
0.624), the KQoL-26 Physical subscale (4 weeks: 8.50,
95 % CI = 1.84 to 15.16, p = 0.018; 12 weeks: 9.33, 95 %
CI 4.56 to 14.11, p = 0.002, ETA = 0.706) and the KQoL
Emotional subscale (4 weeks: 12.08, 95 % CI 3.26 to 20.91,
p = 0.013; 12 weeks: 9.58, 95 % CI 17.11 %, p = 0.009,
ETA = 0.715) (Table 2). For the HA group, significant
improvements were only found in the KOOS Function
subscale at 12 weeks (14.05, 95 % CI 18.59 to 24.15, p =
0.008, ETA = 0.602). Table 2 also demonstrates that the
PA-PRP group significantly improved both hopping
(4 weeks: 13.44, 95 % CI = 2.23 to 24.66, p = 0.025;
12 weeks: 22.33, 95 % CI 11.86 to 32.80, p = 0.001,
ETA = 0.799) and knee bend (12 weeks: 9.78, 95 % CI
5.00 to 14.56, p = 0.002, ETA = 0.756) performance,
whereas changes in physical function in the HA group
were not found to be significant. To investigate between-
group differences in mean change scores on the 100 mm
VAS, KOOS, KQoL-26 and functional tests, ANCOVA
was performed adjusting for baseline scores (Table 3). No
significant between-group differences were found for any
of the self-reported measures or for either of the func-
tional tests (p > 0.05).
Discussion
This was a double-blind randomized controlled pilot study
comparing intra-articular injections of a novel form of
PRP activated with ultraviolet light compared to HA. The
results demonstrate the feasibility of this technique in
people with knee OA and show no serious adverse events
were reported. There was a significant decrease in VAS
pain for the PA-PRP group at four weeks that was greater
than the minimal clinically important improvement level
of 19.9 mm. The 24 % decrease below baseline pain levels
at 12 weeks was not found to be statistically significant
and no improvements in pain were found in the HA
group. The PA-PRP group also demonstrated significant
improvements in the KOOS Pain subscale at four and 12
weeks, and significant improvements in the KQoL-26
Physical and Emotional subscales. In contrast, the only
significant improvement in the HA group was in the
KOOS Functional subscale at 12 weeks. Finally, whilst the
PA-PRP group significantly improved their performance
on the functional measures of hopping and knee bend at
12 weeks, no significant improvements in lower extremity
function were found in the HA group. Despite these im-
provements in the PA-PRP compared to the HA group,
there were no significant between-group differences on
any measures after adjusting for baseline variation. These
preliminary results provide initial feasibility, safety and
treatment data that may be used to inform a future large
clinical trial to investigate whether this novel form of
photo-activated PRP has symptomatic and functional ben-
efits in people with knee OA.
Table 1 Comparison of participant characteristics who completed
the intervention by group
PA-PRP (n = 11) HA (n = 10)
Age, mean (SD) years 49.91 (13.72) 52.70 (10.30)
BMI, mean (SD) kg/m2 27.92 (11.94) 30.87 (5.64)
Previous surgery, no. (%) 5 (45 %) 8 (80 %)
Gender (Male), no. (%) 8 (72.73 %) 7 (70 %)
Symptom duration, mean (SD) years 8.50 (4.95) 15 (7.07)
Cause of osteoarthritis, no.
Degeneration/unknown 6 4
Post joint injury/surgery 3 3
Sport related degeneration 2 3
Legend: SD standard deviation, BMI body mass index, KL Kellgren Lawrence,
PA-PRP photo-activated platelet-rich plasma, HA hyaluronic acid
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Of the 23 people who met the inclusion criteria, two
participants did not complete the allocated intervention
and two additional participants withdrew from the study
following the four week follow-up appointment. These
four patients were evenly spread between groups, and
with the exception of one, were all due to new injuries
unrelated to the treatment. One of the PA-PRP patients
however did withdraw due to minor injection-related
soreness, whilst another two also reported minor pain
and swelling following an injection. In all instances,
symptoms resolved within a week and no further adverse
events were reported during the intervention or follow-
up period.
Previous RCTs have investigated the efficacy of PRP
compared to HA or saline [19, 20, 34, 40, 42, 43]
however to our knowledge this is the first to objectively
evaluate lower limb function and the only one to use
photo-activation of PRP. Photo-activation of peripheral
blood has been previously shown to improve the inflam-
matory cytokine profile of healthy adults [23] and people
with psoriasis [22], and therefore has the potential to
improve outcomes in OA where pro-inflammatory cyto-
kines are critical mediators in the pathophysiology of the
disease [44]. Combined with PRP, which releases growth
factors and other proteins responsible for tissue repair
and inflammatory modulation [45, 46], this may offer a
novel method for improving symptoms and function in
people with knee OA. Our results provide mixed sup-
port for this new treatment approach. Although the PA-
PRP group showed significantly greater improvement in
Table 2 Mean (SD) for VAS, KOOS, KQoL and functional tests at baseline and four and 12 weeks following final injection
PA-PRP HA
Baseline (n = 11) 4 weeks (n = 11) 12 weeks (n = 10) Baseline (n = 10) 4 weeks (n = 10) 12 weeks (n = 9)
Pain VAS 48.09 (23.75) 19.64 (17.61)** 36.89 (25.42) 39.70 (21.90) 12.90 (14.06) 14.13 (9.30)
KOOS Symptoms 48.70 (15.83) 57.14 (20.33) 57.86 (22.76) 62.14 (17.99) 61.07 (26.86) 80.16 (8.40)
Pain 57.07 (11.21) 71.47 (16.67)** 68.89 (15.76)* 70.00 (11.25) 67.22 (25.55) 79.32 (9.33)
Function 70.72 (13.64) 79.27 (15.08) 78.68 (15.87) 75.44 (12.42) 79.12 (28.63) 90.03 (7.31)**
Sport 31.82 (20.40) 40.46 (28.32) 41.00 (27.77) 47.00 (28.69) 46.50 (33.75) 64.44 (23.64)
QoL 30.11 (18.92) 40.89 (27.55) 38.75 (28.38) 41.87 (13.51) 42.50 (21.21) 54.86 (9.77)
KQoL Physical 57.72 (18.35) 65.00 (18.14)* 68.83 (18.64)** 71.16 (14.91) 68.33 (27.54) 80.55 (13.46)
Activity 59.09 (23.33) 72.73 (16.79) 70.00 (22.23) 75.50 (15.71) 78.50 (29.16) 88.89 (7.41)
Emotional 46.97 (26.69) 58.71 (23.68)* 58.75 (29.49)** 58.75 (24.25) 67.08 (29.88) 75.00 (16.00)
Functional tests Hops 46.64 (33.04) 57.64 (41.36)* 79.33 (34.17)** 55.50 (35.43) 51.50 (39.49) 79.25 (38.04)
Knee bends 19.45 (8.25) 22.27 (8.37) 31.44 (7.96)** 20.50 (13.23) 25.30 (16.60) 31.13 (15.63)
Legend: VAS visual analogue score, KOOS knee osteoarthritis outcome score, QoL quality of life, KQoL knee quality of life, PA-PRP photo-activated platelet-rich
plasma, HA hyaluronic acid
*Indicates statistically significant (p < 0.05) improvement from baseline
**Indicates statistically significant (p < 0.01) improvement from baseline
Table 3 Adjusted mean difference (95% confidence intervals; CI) between the two groups for VAS, KOOS, KQoL and functional tests
at baseline and four and 12 weeks following final injection
4 weeks 12 weeks
Mean difference (95 % CI) P value Mean difference (95 % CI) P value
Pain VAS 1.90 (-13..80 to 17.60) 0.79 18.81 (-0.62 to 38.24) 0.06
KOOS Symptoms 7.52 (-17.20 to 32.23) 0.53 −15.57 (-34.12 to 2.99) 0.09
Pain 15.64 (-9.81 to 41.10) 0.21 −4.30 (-19.76 to 11.16 0.56
Function 4.44 (-17.00 to 25.88) 0.67 −8.93 (-19.92 to 2.07) 0.10
Sport 0.66 (-29.31 to 30.62) 0.96 −13.68 (-36.38 to 9.02) 0.22
QoL 11.17 (-6.22 to 28.57) 0.19 −8.09 (-25.11 to 8.93) 0.33
KQoL Physical 10.90 (-9.11 to 30.91) `0.27 −0.41 (-8.59 to 7.77) 0.92
Activity 6.46 (-16.09 to 29.01) 0.55 −11.01 (-25.59 to 3.57) 0.13
Emotional 0.18 (-19.76 to 20.11) 0.99 −11.60 (-28.49 to 5.28) 0.17
Functional tests Hops 17.23 (-19.26 to 53.72) 0.33 8.93 (-5.26 to 23.13) 0.20
Knee bends −0.81 (-9.29 to 7.68) 0.84 1.16 (-9.11 to 11.43) 0.81
Legend: VAS visual analogue scale, KOOS knee osteoarthritis outcome score, QoL quality of life, KQoL knee quality of life, CI confidence intervals
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self-reported symptoms and lower limb physical function
compared to HA, between-group differences were not
significant. It is possible that the small sample size of
our pilot study may have reduced statistical power mak-
ing definitive between-group conclusions difficult.
The lack of between-group differences found in our
pilot study may also be partly due to our PRP prepar-
ation method. We used a double spin technique which
has previously been shown to produce PRP that is higher
in leukocyte concentration when compared to PRP pre-
pared using a single spin technique [34]. Indeed, our
findings are consistent with two recent RCTs report-
ing comparable between-group improvements in self-
reported pain and symptoms following injections of
either PRP prepared using a leukocyte-rich technique
or HA [19, 26]. In contrast, two recent studies investigat-
ing the effects of PRP prepared using a leukocyte-poor
technique, and a recent meta-analysis [47], have suggested
this form of PRP produces improvements in self-reported
symptoms above that of HA. Cerza and colleagues [40]
showed significantly improved overall WOMAC score at
12 and 24 weeks in knee OA patients who had injections
of PRP prepared using a leukocyte-poor technique com-
pared to patients who received HA. Similarly, Sanchez
and colleagues [43] reported that patients with knee OA
who received leukocyte-poor PRP had significant benefits
at 24 weeks compared to those who received HA. The
findings of our study, and those from these previous clin-
ical trials, suggests that leukocyte concentration of PRP
may play a crucial role in clinical outcomes achieved for
knee OA patients. However, future studies should explore
the effects of photo-activation in both leukocyte-rich and
leukocyte-poor PRP preparations given photo-activation is
thought to act at least in part by modulating the pro- and
anti-inflammatory properties of leukocytes [22, 23].
There are some limitations that may have influenced
the outcomes of our study. Firstly, as mentioned the
small sample size of this pilot trial reduces statistical
power which may make more definitive conclusions
problematic, and the relatively short follow-up period of
our study may have been too brief to determine between-
group differences. A larger clinical trial is needed to
confirm our results. Furthermore, we did not include a
minimum VAS pain score as part of our screening criteria,
resulting in greater variation in baseline pain and self-
reported symptoms. This produced high baseline standard
deviations which would have decreased the probability of
finding differences between the PRP and HA groups,
particularly with the small sample size. Finally, we did
not examine how photo-activation modifies PRP.
Given the benefits of photo-activation have been at-
tributed to its influence upon the concentration of
proinflammatory cytokines and leucocyte-derived anti-
inflammatory factors [22, 23], and the potential role
of leukocyte concentration in PRP, this warrant further
investigation.
Conclusions
This randomized controlled pilot study provides feasibil-
ity and safety data for the use of PA-PRP in people with
knee OA that may help to inform a larger clinical trial.
Although under-powered to assess efficacy, our prelim-
inary results also provide some evidence that PA-PRP
improves self-reported pain, subscales of the KOOS and
KQoL-26, and tests of lower extremity functional ability
in knee OA patients. However these improvements were
not found to be significantly greater than those of the
HA group. Future clinical trials with larger sample sizes
and longer follow up periods should investigate
whether this novel photo-activated PRP method im-
proves symptoms and function over that of HA in people
with knee OA.
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